Table 1.
Examples of TWEAK-targeted therapeutic agents for inflammatory and/or neurodegenerative diseases.
| Agent | Developer | Type of agent | Status | Disease | Reference(s) |
|---|---|---|---|---|---|
| Fn14-Fc | EUSOM/UMSOM | Decoy receptor | Pre-clinical | Cerebral ischemia and edema (stroke) | (37, 40, 41) |
| Fn14-TRAIL (KAHR-101) | KAHR Medical | Signal converter protein | Pre-clinical | EAE (model of multiple sclerosis) | (52, 54) |
| BIIB023 | Biogen Idec | Neutralizing mAb | Phase I trial | Rheumatoid arthritis | ClinicalTrials.gov |
| Start date: October 2008 | NCT00771329 | ||||
| Completion date: April 2011 | (68) | ||||
| BIIB023 | Biogen Idec | Neutralizing mAb | Phase II trial | Lupus nephritis | ClinicalTrials.gov |
| Start date: July 2012 (recruiting) | NCT01499355 |
EUSOM, Emory University School of Medicine; UMSOM, University of Maryland School of Medicine; EAE, experimental autoimmune encephalomyelitis; mAb, monoclonal antibody.